Release Summary

Hereditary antithrombin (AT) deficiency, and the use of the rEVO Biologics’ lead product ATryn antithrombin (Recombinant) will be the focus of a TV segment on The Balancing Act January 28 at 7:00am ET

rEVO Biologics